Xella Health is a San Francisco–based women’s precision health company creating multi-omic diagnostics that decode female biology by simultaneously analyzing menstrual fluid and peripheral blood. The platform targets conditions that uniquely, differently, or disproportionately affect women, including fertility challenges, hormonal imbalances, perimenopause, and early-stage cancers. Each customer is paired with a dedicated clinician-coach who is supported by AI, ensuring complex molecular data is translated into actionable care plans rather than just additional information. The company positions itself as foundational infrastructure for women’s health, combining deep biology with clinical translation and accountability to outcomes. Xella Health has raised $3.7 million in pre-seed capital to accelerate product development and clinical validation. No operating metrics such as revenue or user counts were disclosed in the article.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026